Podcast Summary: Tomorrow's Cure - 3D Bioprinted Skin: Breakthroughs in Regenerative Medicine
Podcast: Mayo Clinic Human Optimization Project
Episode Air Date: March 18, 2026
Host: Kathy Werzer
Guests:
- Dr. Sarenya Wiles (Dermatologist, Mayo Clinic)
- Dr. Adam Feinberg (Biomedical Engineer, Carnegie Mellon)
Episode Overview
This episode dives deep into the emerging science of 3D bioprinted skin—its role in regenerative medicine, its promise for patient care (especially for burns and chronic wounds), and the technical, ethical, and practical hurdles of bringing engineered skin from lab to clinic. Dr. Sarenya Wiles and Dr. Adam Feinberg share cutting-edge research and their visions for a future where personalized, functional skin can be designed, printed, and implanted to optimize healing and health.
Key Discussion Points & Insights
1. Rethinking Skin: From Lifespan to "Skin Span"
-
Skin span is an emerging concept, derived from lifespan and health span, reflecting not just how long skin lasts, but how well it functions as a dynamic barrier and organ over time.
- “Skin span is the concept that we can have optimally functioning skin at the level of structure, but also at the level of its function… longer.” — Dr. Wiles [03:06]
-
The skin serves as both a mirror and a sentinel of systemic health.
- “I consider the skin as a mirror to your systemic health… It can show signs. We can tell if there’s something gone awry.” — Dr. Wiles [03:52]
2. The Science and Technology of 3D Bioprinting Skin
-
The approach models skin’s natural “cake layers”: epidermis, dermis, hypodermis.
- Engineers and physicians work to print these layers using native human tissue: cells, collagen, and more.
-
Bioprinting technology (such as extrusion bioprinting) allows layer-by-layer recreation of skin’s complexity with specific cells (e.g., fibroblasts for the dermis, keratinocytes & melanocytes for the epidermis).
- “We are trying to model the cake layers of the skin… lay out the different cells that would go into each component of the cake layer.” — Dr. Wiles [07:35]
-
The shift away from synthetic materials:
- “We just wanted to use the same materials as the human body… not synthetic materials, plastics, ceramics, metals…our system is designed to work with entirely biologic materials.” — Dr. Feinberg [06:07]
3. Real-World Impact: Research to Clinical Application
-
Diagnostic and Therapeutic Models:
- Bioprinted skin is already valuable for preclinical testing—offering a human-relevant alternative to animal models (e.g., for eczema drug testing) [09:26]
- “We want to create a system that is an alternate to animal testing… to see if we can utilize these models as preclinical testing.” — Dr. Wiles [09:26]
-
Collagen in Bioprinting:
- Collagen is the body’s fundamental scaffolding. Recent bioprinting advances allow for highly accurate, biomimetic collagen structures, making engineered skin genuinely “human-like.”
- “Now we can 3D print collagen that under the best electron microscopes looks like collagen should.” — Dr. Feinberg [10:33]
- Collagen is the body’s fundamental scaffolding. Recent bioprinting advances allow for highly accurate, biomimetic collagen structures, making engineered skin genuinely “human-like.”
-
Regenerating Complex Tissues:
- The focus expands from skin patches for burns to “volumetric tissue regeneration”—entire sections of limb tissue, leveraging patient scans and decellularized scaffolds. [16:06]
4. Zombie Cells (Senescent Cells) and Aging
-
Senescent “zombie cells” are non-dividing cells that accumulate with aging, affecting healing and overall tissue function.
- “Zombie cells, or senescent cells, are cells that… are no longer dividing but they don’t die off.” — Dr. Wiles [18:15]
- These cells send disruptive “noise” (SASP) that can even impact cognition and systemic health.
- “This noise is pervasive, so it can actually affect… other organ systems… cognitive function.” — Dr. Wiles [19:56]
-
Senescence in other organs:
- Similar model work in engineered heart tissue reveals chemotherapy-induced heart failure is also linked to accelerated senescence.
- “The chemotherapy was inducing a much higher rate of senescence in the heart muscle cells.” — Dr. Feinberg [20:52]
- Similar model work in engineered heart tissue reveals chemotherapy-induced heart failure is also linked to accelerated senescence.
5. The Push for Human-Relevant, Inclusive Models
-
Validation and Variability Challenges:
- Ensuring bioprinted tissues accurately replicate real human pathology is complex (working with dermatopathologists, monitoring cytokines, etc.).
- The FDA is moving toward human tissue models for drug testing, but inter-individual variability remains a major hurdle.
- “The value and potential of the models… but validating that they’re predictive will be the challenge going forward.” — Dr. Feinberg [24:15]
-
Inclusivity and Rare Diseases:
- Bioprinted skin opens the door for testing therapies across a diverse range of skin types and rare diseases, which have been neglected due to lack of accessible in vivo models.
- “Now we’re opening up new ways to study rare diseases, patients that we wouldn’t have been able to utilize or diagnose before.” — Dr. Wiles [25:51]
- Bioprinted skin opens the door for testing therapies across a diverse range of skin types and rare diseases, which have been neglected due to lack of accessible in vivo models.
6. Ethical, Philosophical, and Accessibility Considerations
-
Moving away from animal testing, the technology must remain inclusive (accommodating diverse skin pigmentation) and accessible (cost-effective platforms).
-
Bioprinter democratization:
- Dr. Feinberg’s lab runs open-source bioprinting workshops, enabling others to build powerful bioprinters for ~$1,000—radically reducing barriers and encouraging innovation.
- “We decided… let’s create a workshop where you can come to Carnegie Mellon, build your own 3D bioprinter, and take it back with you.” — Dr. Feinberg [29:00]
- Dr. Feinberg’s lab runs open-source bioprinting workshops, enabling others to build powerful bioprinters for ~$1,000—radically reducing barriers and encouraging innovation.
-
Interdisciplinary collaboration is essential:
- “There’s something magical that happens when engineers and physicians meet in a room.” — Dr. Wiles [32:46]
7. Barriers and Road Ahead
-
The greatest challenges are not just technical, but also about problem definition, regulatory alignment (with FDA/NIH), establishing the first clinical “wins,” and scaling up manufacturing.
- “The biggest barrier is to try to define the problem… focusing on things like organ replacement and wound patches.” — Dr. Wiles [33:46]
- “We really need to demonstrate that this technology can change the practice of medicine for the better.” — Dr. Feinberg [34:29]
-
Deployment will require adopting lessons from other industries (automotive, software) and integrating AI for quality and interpretation at scale. [36:28]
Notable Quotes & Memorable Moments
- “Our skin is the boundary between the inner and outer world. It’s a mirror of our health and our age.” — Kathy Werzer [01:29]
- “Now we can 3D print collagen that… looks like collagen should. Which means when we implant it, the body recognizes it as normal collagen.” — Dr. Feinberg [10:33]
- “Zombie cells… are no longer dividing but they don’t die off. Initially it’s a good thing for cancer prevention, but over time… these cells can accumulate.” — Dr. Wiles [18:15]
- “Innovation does not need to be expensive. I think innovation really comes from folks like my lab working with folks like Dr. Wiles…” — Dr. Feinberg [32:46]
- “There’s something magical that happens when engineers and physicians meet in a room…” — Dr. Wiles [32:46]
- “It’s hard to have more impact than [changing] human lifespan, human quality of life. I have no doubt this technology is coming.” — Dr. Feinberg [37:13]
Important Timestamps
- 03:06 – Skin span: optimizing for function, not just years.
- 07:35 – Bioprinting process: building “cake layers” of skin.
- 10:33 – Collagen as the main building block and 3D printing advances.
- 16:06 – Regenerating complex tissues for burn and blast injuries.
- 18:15 – Senescent (zombie) cells and their dual role in aging & healing.
- 20:52 – Chemotherapy, senescence, and engineered heart tissue insights.
- 24:15 – Challenges of validation and variability in engineered models.
- 25:51 – Opportunities for inclusivity and rare disease research.
- 29:00 – Democratizing bioprinting: Open-source, hands-on workshops.
- 33:46 – Major barriers: Defining clinical problems and regulatory path.
- 36:28 – The long road to clinical-grade, scalable bioprinted skin.
- 37:13 – Driving inspiration for reinventing medicine and life quality.
Tone & Language
The conversation is enthusiastic, jargon-light, and driven by both scientific marvel and clinical urgency. Both experts are passionate about the potential for real human benefit, while candid about the challenge and time-scale ahead. The interplay between machine (engineering) and medicine is repeatedly celebrated, with a forward-looking, optimistic spirit.
This episode offers listeners a clear, engaging journey across the frontier of skin regeneration, bridging biology, technology, ethics, and patient care—from the promise of personalized wound patches to the future of organ replacement. It showcases the transformative potential of interdisciplinary collaboration—not just in pushing science forward, but in making the future more equitable and accessible.
